You can buy or sell AERI and other stocks, options, ETFs, and crypto commission-free!
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. Read More The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Durham, North Carolina
52 Week High
52 Week Low
Seeking AlphaMar 18
Aerie Pharma launches mid-stage study of AR-1105
Aerie Pharmaceuticals (AERI -0.9% ) initiates a Phase 2 clinical trial evaluating AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion.
Aerie Pharma (AERI) Begins Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with RVO
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This Phase 2 study (AR1105-CS201) will be conducted at approximately 20 centers in the United States and enroll up to 45 patients. The primary objectives of the trial are to evaluate the safety, tolerability and efficacy of the AR-1105 dexamethasone int...
Yahoo FinanceMar 13
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
Aerie Pharmaceuticals, Inc. (AERI announced that the FDA has approved Rocklatan 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rocklatan is a once-daily, quadruple-action fixed-dose combination of Rhopressa (netarsudil) and Pfizer’s PFE Xalatan (latanoprost). The FDA approval was supported by data from two phase III registration studies, MERCURY 1 and MERCURY 2. In these studies, Rocklatan achieved its primary 90-day efficacy endpoint...
Expected May 7, After Hours